Keywords: BioAlliance, Sitavig, Labial herpes, EU approvals

BioAlliance gains registration of Sitavig in eight European countries

Article | 20 December 2012

Print This

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the approval of Sitavig (acyclovir Lauriad) for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in